Regulus Therapeutics Inc
RGLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$564.95M
Close$
$0.68
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $564.95 Million |
|---|---|
| Enterprise Value | $517.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.82 |
| Beta | 0.37 |
| Outstanding Shares | 66,174,550 |
Return
| Return on Equity | -68.85% |
|---|---|
| Return on Assets | -63.51% |
| Return on Invested Capital | -72.11% |
Valuation & Multiples
| P/E Ratio | -24.08 |
|---|---|
| PEG | -175.05 |
| Price to Sales | - |
| Price to Book Ratio | 8.16 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.18 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Regulus Therapeutics Inc
24 employees
CEO: Joseph Hagan Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop ...